However, therapeutic responses to TGF-β blockade are likely to be heterogeneous, influenced by tumor subtype, disease stage, baseline immune contexture, and stromal composition, emphasizing the importance of identifying predictive biomarkers and defining patient populations most likely to benefit. Here, TGFB1 is linked to neoplasm.